Scarica l'app Stockscreener
47.09
1.42%
0.66
Pre-mercato:
46.76
-0.33
-0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Why CRISPR Therapeutics AG (CRSP) Performed Better Than the Market Today - Bitget
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today - Yahoo Finance Singapore
CRISPR Therapeutics stock dips on $350M convertible debt offering - MSN
CRISPR Therapeutics (NASDAQ:CRSP) General Counsel James Kasinger Sells 3,182 Shares - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,020 Shares - MarketBeat
Crispr Therapeutics Insider Sold Shares Worth $468,736, According to a Recent SEC Filing - marketscreener.com
CRISPR (CRSP) GC granted options, RSUs; sells shares for taxes - Stock Titan
CRISPR Therapeutics (CRSP) CEO gets major equity awards, sells shares for taxes - Stock Titan
[Form 4] CRISPR Therapeutics AG Insider Trading Activity - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) grants CMO stock options and RSUs - Stock Titan
CRISPR Therapeutics Hits Day Low of $45.88 Amid Price Pressure - Markets Mojo
Anti-Aging Protein Research Takes a Step Forward with Cell Cloning - Benzinga
What's going on with CRISPR Therapeutics stock today? - MSN
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance Singapore
CRSP Stock Price, Quote & Chart | CRISPR THERAPEUTICS AG (NASDAQ:CRSP) - ChartMill
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - MSN
JPMorgan Chase & Co. Has $38.46 Million Holdings in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is why CRISPR Therapeutics (CRSP) appears so good - MSN
CRISPR Therapeutics AG (CRSP) registers a bigger fall than the market: Important facts to note - MSN
This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough. - Barchart
Is CRISPR Therapeutics Stock a Buy Now? - The Motley Fool
Assessing CRISPR Therapeutics (CRSP) Valuation After CASGEVY Traction And US$600m Convertible Notes Raise - Sahm
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
CRISPR Therapeutics gains amid takeover speculation - MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know - MSN
CRISPR Therapeutics AG (CRSP) Declines Sharply Compared to Overall Market: Essential Information for Investors - Bitget
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
CRISPR Therapeutics AG Bonds — Corporate Bond Rates - TradingView
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
CRISPR Therapeutics (CRSP) Is Down 5.1% After $550M Convertible Notes OfferingHas The Bull Case Changed? - simplywall.st
(CRSP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Piper Sandler raises CRISPR Therapeutics price target on cash raise By Investing.com - Investing.com South Africa
Volatility Watch: Is CRISPR Therapeutics AG showing insider buyingInsider Selling & Proven Capital Preservation Tips - baoquankhu1.vn
Insider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells 10,349 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Insider Naimish Patel Sells 3,150 Shares of Stock - MarketBeat
CRISPR Therapeutics (NASDAQ: CRSP) CMO vests RSUs, mandated tax sale - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift - Stock Titan
CRISPR Therapeutics (NASDAQ: CRSP) GC sells shares for tax withholding - Stock Titan
CRISPR Therapeutics (CRSP) CEO logs RSU vesting and tax-driven share sale - Stock Titan
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Crispr Therapeutics Completes $600 Million Convertible Notes Offering - The Globe and Mail
Goodwin Guides CRISPR Therapeutics On Pricing $550 Million Upsized Convertible Senior Notes Offering - Mondaq
Piper Sandler Raises Price Target for CRSP to $110, Reiterates O - GuruFocus
Is CRISPR Therapeutics (CRSP) the best gene-editing stock to buy now? - MSN
Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? - Insider Monkey
CRISPR Therapeutics (NASDAQ:CRSP) Receives Overweight Rating from Piper Sandler - MarketBeat
Piper Sandler raises CRISPR Therapeutics price target on cash raise - Investing.com
CRISPR Therapeutics (NASDAQ: CRSP) sells $600M 2031 convertible notes - Stock Titan
CRISPR Therapeutics AG Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ark Invest Increases Holdings in CRISPR Therapeutics (CRSP) - GuruFocus
Investors heavily search CRISPR Therapeutics AG (CRSP): Here is what you need to know - MSN
Clough Capital Partners L P Makes New $1.49 Million Investment in CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics prices $550M convertible notes offering By Investing.com - Investing.com Nigeria
Is CRISPR Therapeutics (CRSP) Pricing Reflecting Gene Editing Potential After Recent Share Pullback - Yahoo Finance
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story - Sahm
CRISPR Therapeutics shares drop after announcing convertible notes sale - MSN
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):